Novavax (NVAX) Income towards Parent Company (2010 - 2026)
Novavax's (NVAX) quarterly Income towards Parent Company came in at -$9.5 million in Q1 2026, down 101.83% year-on-year from $518.6 million in Q1 2025, and down 154.15% quarter-over-quarter from $17.5 million in Q4 2025.
Novavax (NVAX) Income towards Parent Company (2010 - 2026) Analysis & Trends
Novavax's Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$9.5 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 101.83% year-over-year to -$9.5 million in Q1 2026; TTM through Mar 2026 was -$87.8 million, a 118.35% decrease from a year earlier, with the FY2025 full-year figure at $440.3 million, up 334.83% from the prior year.
- Income towards Parent Company slipped to -$9.5 million in Q1 2026 per NVAX's latest filing, from $17.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $518.6 million in Q1 2025 and bottomed at -$510.5 million in Q2 2022.
- The 5-year median for Income towards Parent Company is -$121.3 million (2024), against an average of -$56.5 million.
- Across the five-year window, Income towards Parent Company slumped 244.49% in 2023 and surged 451.51% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$182.2 million in 2022, then rose by 2.12% to -$178.4 million in 2023, then jumped by 54.58% to -$81.0 million in 2024, then jumped by 121.63% to $17.5 million in 2025, then slumped by 154.15% to -$9.5 million in 2026.
- Per Business Quant, the three latest NVAX Income towards Parent Company figures stand at -$9.5 million (Q1 2026), $17.5 million (Q4 2025), and -$202.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.49 Mn |
| Dec 31, 2025 | 17.53 Mn |
| Sep 30, 2025 | -202.38 Mn |
| Jun 30, 2025 | 106.51 Mn |
| Mar 31, 2025 | 518.65 Mn |
| Dec 31, 2024 | -81.03 Mn |
| Sep 30, 2024 | -121.30 Mn |
| Jun 30, 2024 | 162.38 Mn |
| Mar 31, 2024 | -147.55 Mn |
| Dec 31, 2023 | -178.39 Mn |
| Sep 30, 2023 | -130.78 Mn |
| Jun 30, 2023 | 58.01 Mn |
| Mar 31, 2023 | -293.91 Mn |
| Dec 31, 2022 | -182.25 Mn |
| Sep 30, 2022 | -168.61 Mn |
| Jun 30, 2022 | -510.49 Mn |
| Mar 31, 2022 | 203.41 Mn |
| Dec 31, 2021 | -846.28 Mn |
| Sep 30, 2021 | -322.43 Mn |
| Jun 30, 2021 | -352.32 Mn |